|Catalog||Size (Price)||Quantity||In Stock||Operation||Other Information|
CDKN2D / p19ink4d Antibody Datasheet
|Order or Inquire for CDKN2D / p19ink4d Antibody product||Quality antibodies||Antibody production services|
|Detection limit is 0.0195 ng/well in ELISA|
CDKN2D / p19ink4d Antibody Product Information
Recombinant Human CDKN2D / p19ink4d protein (Catalog#12558-H09E)
|Antibody Type :||Mouse Monoclonal Antibody ( Mouse mAb Service Platform )|
Clone ID :
|Ig Type :||
|Formulation :||0.2 μm filtered solution in PBS with 5% trehalose|
This antibody was produced from a hybridoma resulting from the fusion of a mouse myeloma with B cells obtained from a mouse immunized with purified, recombinant Human CDKN2D / p19ink4d (rh CDKN2D / p19ink4d; Catalog#12558-H09E; P55273; Met 10-Leu 166). The IgG fraction of the cell culture supernatant was purified by Protein A affinity chromatography.
CDKN2D / p19ink4d Antibody Usage Guide
Human CDKN2D / p19ink4d
No cross-reactivity in ELISA with
E.coli cell lysate
|Direct ELISA :||This antibody can be used at 0.5-1 μg/mL with the appropriate secondary reagents to detect Human CDKN2D. The detection limit for Human CDKN2D is approximately 0.0195 ng/well.|
|Storage :||This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -70℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
CDKN2D / p19ink4d Antibody Related Products & Topics
|Molecule||Species||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|CDKN2D||Human||CDKN2D / p19ink4d Protein,Recombinant, with GST Tag||12558-H09E|
|Molecule||Application||Description //For Detailed Info. and Price------CLICK!||Cat. No|
|Human CDKN2D||WB, ELISA||CDKN2D / p19ink4d Antibody||12558-MM06|
CDKN2D / p19ink4d Antibody Background
Cyclin-dependent kinase inhibitor 2D (also known as CDKN2D or p19ink4d), a member of the INK4 family of cyclin-dependent kinase (CDK) inhibitors, negatively regulates the cyclin D-CDK4/6 complexes, which promote G1/S transition by phosphorylating the retinoblastoma tumor-suppressor gene product. It is clearly shown that DNA repair is the main target of p19ink4d effect and that diminished apoptosis is a downstream event. Experiments has uncovered a role of p19INK4d as a regulator of DNA-damage-induced apoptosis and suggest that it protects cells from undergoing apoptosis by allowing a more efficient DNA repair. It has been demonstrated that p19INK4d expression enhances cell survival under genotoxic conditions. p19INK4d expression correlates with the cellular resistance to UV treatment with increased DNA repair activity against UV-induced lesions. On the contrary, cells transfected with p19INK4d antisense cDNA show reduced ability to repair DNA damage and increased sensitivity to genotoxic insult when compared with their p19INK4d-overexpressing counterparts. Previous work has shown that inactivation of the cyclin-dependent kinase inhibitor (CKI) p19 (Ink4d) leads to progressive hearing loss attributable to inappropriate DNA replication and subsequent apoptosis of hair cells. It may also involved in male reproductive function including testicular atrophy, alteration in serum follicle stimulating hormone, qualitative increase in germ cell apoptosis, and delayed kinetics of meiotic prophase markers.
- Buchold GM. et al., 2007, Mol Reprod Dev. 74 (8): 1008-20.
- Laine H. et al., 2007, J Neurosci. 27 (6): 1434-44.
- Ceruti JM. et al., 2005, Oncogene. 24 (25): 4065-80.